33:e4368
The change from baseline at 26 weeks (T2D study) or 36 weeks (obesity study) in blood pressure, lipids (cholesterol, triglycerides, Apolipoprotein B (ApoB), Apolipoprotein C3 (ApoC3), N-terminal pro-b-type natriuretic peptide (NT-pro-BNP), and inflammatory biomarkers (high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6)) were assessed
While both compounds work through different mechanisms that theoretically could complement each other, the safety, efficacy, and optimal dosing of this combination remain completely unknown
History of Seizures Bupropion can potentially increase the risk of seizures depending on the dose
Adverse events occurred among 75% of adults receiving orforglipron 12 mg, 75% receiving orforglipron 36 mg, 71% receiving oral semaglutide 7 mg and 72% receiving oral semaglutide 14 mg